WALTHAM, Mass., Feb. 17, 2012 (GLOBE NEWSWIRE) -- On-Q-ity, a life sciences company focused on novel circulating tumor cell (CTC) capture and characterization for clinical researchers and physicians that will enhance decision-making across multiple cancer types, today announced that it will be a corporate sponsor of the Molecular Medicine Tri-Conference being held in San Francisco February 21-23 and will be presenting during the Circulating Tumor Cells Conference Program.
Denis Smirnov, Ph.D., Director of Molecular Characterization at On-Q-ity, will be giving a talk on Tuesday, February 21st, on On-Q-ity's CTC platform entitled: "A Microfluidic System for the Selection of Circulating Tumor Cells that Utilizes both Affinity and Size Capture Technologies." Dr. Smirnov recently presented data on On-Q-ity's CTC technology at Select Bioscience's Circulating Tumor Cell Conference in San Diego February 2-3.
The Tri-Conference luncheon talk will take place during the first day of the Circulating Tumor Cell track meetings:
Moscone North Convention Center, Room 133
Circulating Tumor Cells Conference Program
Tuesday, Feb 21, 12:55-1:25
For more information about the Molecular Medicine Tri-Conference please visit www.tri-conference.com.
About On-Q-ity
On-Q-ity is a life sciences company focused on novel circulating tumor cell (CTC) capture and characterization. We are developing products and services for clinical researchers and physicians that will enhance decision-making across multiple cancer types. On-Q-ity envisions a time when cancer is transformed from a fatal to chronic disease via CTC technology, further enabling the promise of personalized medicine. Our goals are to increase the success of oncology drug development, improve patient treatment outcomes and increase survival rates. Headquartered in Waltham, MA, On-Q-ity is currently funded by Atlas Venture, Mohr Davidow and Physic Ventures. For more information visit our website: www.On-Q-ity.com